Pharsight

Xiidra generic

Xiidra is an ophthalmic solution owned by Novartis. The active ingredient in Xiidra is lifitegrast which has shown efficacy in treating the signs and symptoms of dry eye disease. The drug first received market authorization on 11 July, 2016.

When will Xiidra generic be available?

The generic version of Xiidra can be anticipated after 18 December, 2033. This is tied to the expiration date of its last patent. The release of a generic version might occur sooner if a Para IV filing is introduced.

Xiidra uses

Xiidra's active ingredient, lifitegrast, aids in treating the signs and symptoms of dry eye disease. This medication works by blocking a certain protein on the surface of cells in your body that can lead to inflammation and dry eyes. Hence, Xiidra is primarily used for the treatment of signs and symptoms of dry eye disease.

Xiidra patent expiration

Xiidra, a medication by Novartis, holds 16 patents. None of these patents have expired, ensuring that a Xiidra generic can't be released yet. The last patent for Xiidra, under the title 'LFA-1 inhibitor formulations', is scheduled to expire on 18 December, 2033. Below are the details of the patent:

Xiidra dosage

Want to ask something?